Clinical trials: Periampullary Carcinoma Resectable, open to volunteers
Pancreas Cancer, Periampullary Cancer
Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer
Adjuvant chemotherapy after surgery significantly improved the survival of pancreatic cancer (PC) patients, but there is a problem that only about 50% of patients start adjuvant chemotherapy after pancreatectomy.
- Conditions
- Pancreas Cancer, Periampullary Cancer, Periampullary Carcinoma Resectable, Pancreatic Cancer Resectable
- Trial name
- NCT07081360
- Testing
- Neoadjuvant chemotherapy, Upfront Surgery Group
- Where
- Egypt
- Volunteers
- 262 people
- Sponsor
- Minia University
Pancreas Cancer, Pancreas Neoplasm
Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy
Pancreaticoduodenectomy (PD) is a complex procedure performed in patients with malignant or benign tumors of the pancreatic head and periampullary region, associated with high morbidity and mortality.
- Conditions
- Pancreas Cancer, Pancreas Neoplasm, Pancreatic Fistula, Pancreas Adenocarcinoma
- Trial name
- POPF (NCT07022015)
- Testing
- pancreaticoduodenectomy procedure
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Minia University
Periampullary Carcinoma Resectable
The Effect of Braun Anastomosis on Delayed Gastric Emptying (DGE) in Reconstruction After Pancreaticoduodenectomy
Pancreaticoduodenectomy (PD) is the only curative procedure for periampullary malignant tumors. Although modern perioperative management has greatly reduced postoperative mortality, delayed gastric emptying (DGE) remains one of…
- Trial name
- NCT07681128
- Testing
- Braun anastomosis on delayed gastric emptying (DGE) in reconstruction after pancreaticoduodenectomy, Patients undergo PD with standard antecolic Billroth II reconstruction without Braun enteroenterostomy.
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital